Drug targets for heart failure with preserved ejection fraction

A mechanistic approach and review of contemporary clinical trials

Ravi B. Patel, Sanjiv J Shah

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for over half of prevalent heart failure (HF) worldwide, and prognosis after hospitalization for HFpEF remains poor. Due, at least in part, to the heterogeneous nature of HFpEF, drug development has proved immensely challenging. Currently, there are no universally accepted therapies that alter the clinical course of HFpEF. Despite these challenges, important mechanistic understandings of the disease have revealed that the pathophysiology of HFpEF is distinct from that of HF with reduced ejection fraction and have also highlighted potential new therapeutic targets for HFpEF. Of note, HFpEF is a systemic syndrome affecting multiple organ systems. Depending on the organ systems involved, certain novel therapies offer promise in reducing the morbidity of the HFpEF syndrome. In this review, we aim to discuss novel pharmacotherapies for HFpEF based on its unique pathophysiology and identify key research strategies to further elucidate mechanistic pathways to develop novel therapeutics in the future.

Original languageEnglish (US)
Pages (from-to)41-63
Number of pages23
JournalAnnual Review of Pharmacology and Toxicology
Volume59
DOIs
StatePublished - Jan 6 2019

Fingerprint

Heart Failure
Clinical Trials
Pharmaceutical Preparations
Drug therapy
Therapeutics
Hospitalization
Morbidity
Drug Therapy
Research

Keywords

  • Heart failure with preserved ejection fraction
  • Pathophysiology
  • Pharmacotherapy

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

@article{fade26e752194de38ab1a4a12e063994,
title = "Drug targets for heart failure with preserved ejection fraction: A mechanistic approach and review of contemporary clinical trials",
abstract = "Heart failure with preserved ejection fraction (HFpEF) accounts for over half of prevalent heart failure (HF) worldwide, and prognosis after hospitalization for HFpEF remains poor. Due, at least in part, to the heterogeneous nature of HFpEF, drug development has proved immensely challenging. Currently, there are no universally accepted therapies that alter the clinical course of HFpEF. Despite these challenges, important mechanistic understandings of the disease have revealed that the pathophysiology of HFpEF is distinct from that of HF with reduced ejection fraction and have also highlighted potential new therapeutic targets for HFpEF. Of note, HFpEF is a systemic syndrome affecting multiple organ systems. Depending on the organ systems involved, certain novel therapies offer promise in reducing the morbidity of the HFpEF syndrome. In this review, we aim to discuss novel pharmacotherapies for HFpEF based on its unique pathophysiology and identify key research strategies to further elucidate mechanistic pathways to develop novel therapeutics in the future.",
keywords = "Heart failure with preserved ejection fraction, Pathophysiology, Pharmacotherapy",
author = "Patel, {Ravi B.} and Shah, {Sanjiv J}",
year = "2019",
month = "1",
day = "6",
doi = "10.1146/annurev-pharmtox-010818-021136",
language = "English (US)",
volume = "59",
pages = "41--63",
journal = "Annual Review of Pharmacology and Toxicology",
issn = "0362-1642",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Drug targets for heart failure with preserved ejection fraction

T2 - A mechanistic approach and review of contemporary clinical trials

AU - Patel, Ravi B.

AU - Shah, Sanjiv J

PY - 2019/1/6

Y1 - 2019/1/6

N2 - Heart failure with preserved ejection fraction (HFpEF) accounts for over half of prevalent heart failure (HF) worldwide, and prognosis after hospitalization for HFpEF remains poor. Due, at least in part, to the heterogeneous nature of HFpEF, drug development has proved immensely challenging. Currently, there are no universally accepted therapies that alter the clinical course of HFpEF. Despite these challenges, important mechanistic understandings of the disease have revealed that the pathophysiology of HFpEF is distinct from that of HF with reduced ejection fraction and have also highlighted potential new therapeutic targets for HFpEF. Of note, HFpEF is a systemic syndrome affecting multiple organ systems. Depending on the organ systems involved, certain novel therapies offer promise in reducing the morbidity of the HFpEF syndrome. In this review, we aim to discuss novel pharmacotherapies for HFpEF based on its unique pathophysiology and identify key research strategies to further elucidate mechanistic pathways to develop novel therapeutics in the future.

AB - Heart failure with preserved ejection fraction (HFpEF) accounts for over half of prevalent heart failure (HF) worldwide, and prognosis after hospitalization for HFpEF remains poor. Due, at least in part, to the heterogeneous nature of HFpEF, drug development has proved immensely challenging. Currently, there are no universally accepted therapies that alter the clinical course of HFpEF. Despite these challenges, important mechanistic understandings of the disease have revealed that the pathophysiology of HFpEF is distinct from that of HF with reduced ejection fraction and have also highlighted potential new therapeutic targets for HFpEF. Of note, HFpEF is a systemic syndrome affecting multiple organ systems. Depending on the organ systems involved, certain novel therapies offer promise in reducing the morbidity of the HFpEF syndrome. In this review, we aim to discuss novel pharmacotherapies for HFpEF based on its unique pathophysiology and identify key research strategies to further elucidate mechanistic pathways to develop novel therapeutics in the future.

KW - Heart failure with preserved ejection fraction

KW - Pathophysiology

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=85059797749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059797749&partnerID=8YFLogxK

U2 - 10.1146/annurev-pharmtox-010818-021136

DO - 10.1146/annurev-pharmtox-010818-021136

M3 - Review article

VL - 59

SP - 41

EP - 63

JO - Annual Review of Pharmacology and Toxicology

JF - Annual Review of Pharmacology and Toxicology

SN - 0362-1642

ER -